Recent news on Oxaliplatin

Trade gambit doubles cost of cancer medicine  -  25 May 2007
Globe and Mail,The regulation changes will give Sanofi-aventis Canada eight years of market exclusivity over the colorectal cancer drug oxaliplatin as soon as the firm

Coca-Cola To Buy Glaceau, Maker Of Vitaminwater, For $4.1 Bln ...  -  25 May 2007
RTT News,...survival for mCRC patients who have progressed on, or following fluoropyrimidine-, oxaliplatin-, and irinotecan-containing chemotherapy regimens.

NCCN Updates Esophageal and Gastric Cancer Guidelines  -  May 22, 2007
Business Wire (press release),The REAL 2 study, the largest ever phase III study in advanced esophageal and gastric cancer, found that Capecitabine may replace 5-FU and Oxaliplatin may

Navarra spin-out signs drug deal to develop Hepatitis C treatment  -  May 4, 2007
Science Business (subscription),...of marketed chemotherapeutics and biologics, including doxorubicin, irinotecan, oxaliplatin, cisplatin, paclitaxel, and bevacizumab (AVASTIN®).

Final Vectibix Positive Pivotal Phase 3 Trial Results In ...  -  May 1, 2007
PharmaLive.com (press release),...care (BSC) in metastatic colorectal cancer patients who had failed fluoropyrimidine, irinotecan, and oxaliplatin containing chemotherapy regimens.

Advance in colorectal cancer  -  May 7, 2007
Citrus County Chronicle,The EPIC study of Erbitux in second-line therapy was conducted in 1300 patients with colorectal cancer who had already shown resistance to oxaliplatin.

Fights cancer with healthy dose of vigour  -  May 7, 2007
Ottawa Citizen (subscription),...is attached to a portable waist-pack bag whose battery-driven pump delivers a powerful chemotherapy dose of oxaliplatin to combat his colon cancer.

Sanofi raises profit forecast despite Ambien generic threat  -  May 3, 2007
Pharma Times (subscription),Eloxatin (oxaliplatin) slipped just 3.2% to 393 million euros and Amaryl (glimepiride) for diabetes was down 19% to 94 million euros.

Bevacizumab Useful Adjunct in Metastatic Colon Cancer  -  May 2, 2007
Cancerpage.com,NEW YORK MAY 01, 2007 (Reuters Health) - Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) increases survival in patients

EGFR-Targeted Therapies for Colorectal Cancer Linked to Lower ...  -  May 1, 2007
MedPage Today,...and folinic acid and/or oxaliplatin (Eloxatin). Matuxumab was studied in combination with irinotecan and panitumumab was studied as monotherapy.

Pro-Pharmaceuticals And Digna Biotech Sign Agreement To Apply  -  May 1, 2007
Chemical Online.com (press release),...derivatives of marketed chemotherapeutics and biologics, including doxorubicin, irinotecan, oxaliplatin, cisplatin, paclitaxel, and bevacizumab.

Alchemia Reports Preliminary Positive Efficacy Data From HyCAMP ...  -  Apr 25, 2007
PR Newswire (press release),31 (40.8) Age (Years) n 35 41 76 Median 63.11 62.30 62.67 ECOG Status 0 16 19 45 1 19 22 31 Prior oxaliplatin therapy n 30 34 64 Primary Endpoint 1.

Erbitux® Improves Outcomes in Advanced Colorectal Cancer  -  26 Apr 2007
Cancer Consultants (press release),1] The study enrolled more 1298 patients with metastatic colorectal cancer that was resistant to Eloxatin® (oxaliplatin). Half the patients were treated

Alchemia Reports Preliminary Positive Efficacy Data From HyCAMP ...  -  26 Apr 2007
PR Newswire (press release),31 (40.8) Age (Years) n 35 41 76 Median 63.11 62.30 62.67 ECOG Status 0 16 19 45 1 19 22 31 Prior oxaliplatin therapy n 30 34 64 Primary Endpoint 1.

Cetuximab-Irinotecan Improves Progression-Free Survival and ...  -  Apr 17, 2007
DG NewsThe fact that the patients in this study had failed oxaliplatin therapy was important to the study, explained Alberto Sobrero, MD, department of medical

Access Pharmaceuticals Announces Poster Presentations on ProLindac ...  -  Apr 16, 2007
PharmaLive.com (press release),The first poster is entitled "Antiproliferative effects of ProLindac, a novel DACH-platinum linked polymer-compound, compared to oxaliplatin and cisplatin

Merck's Erbitux increases survival in metastatic colorectal cancer ...  -  Apr 18, 2007
SpiritIndia,There are limited treatment possibilities available for patients whose cancers have progressed on oxaliplatin-based therapies.

Onconova Therapeutics Announces Presentation of Clinical and Non ...  -  Apr 16, 2007
PharmaLive.com (press release),Na was shown for all tumor types tested and this effect was enhanced by combining with Oxaliplatin in the liver, prostate and melanoma tumor models.

Merck KGaA's Erbitux ups survival 50% in colorectal cancer  -  Apr 17, 2007
Pharma Times (subscription),There are limited possibilities available for patients whose cancers have progressed on oxaliplatin-based therapies. These findings demonstrate that the

Roche Submits Application to the FDA for use of XELOX (Xeloda(R ...  -  Apr 5, 2007
Drug Newswire (press release),XELOX is an abbreviation for a type of combination chemotherapy used to treat colorectal cancer; it contains XELODA (capecitabine) plus oxaliplatin.

Roche Files Avastin, Xeloda for New Use in Europe  -  Apr 17, 2007
Reuters.uk,The filing aimed to extend the label of Xeloda, an oral chemotherapy, in combination with oxaliplatin and Avastin for advanced colorectal cancer.

Xeloda Approved in Europe for the Treatment of Advanced Stomach Cancer  -  Mar 29, 2007
campus med,In fact, the REAL 2 study showed patients on one of the Xeloda-containing arms (EOX - epirubicin, oxaliplatin and Xeloda) lived significantly longer than

Xeloda Approved In Europe For The Treatment Of Advanced Stomach Cancer  -  Apr 2, 2007
Medical News Today (press release),In addition, Roche is running a large Phase III program in early stage colon cancer, which includes Xeloda in combination with oxaliplatin (XELOX) with or

Amgen Discontinues Vectibix(TM) Treatment In PACCE Trial ...  -  Apr 2, 2007
Medical News Today (press release),The PACCE trial investigated a treatment regimen that used dual biologics combined with oxaliplatin- or irinotecan-based chemotherapy.

ImClone Systems Showcases Extensive Research and Development ...  -  Apr 19, 2007
PharmaLive.com (press release),Results presented by Deevi et al. show that ERBITUX may also reverse oxaliplatin resistance. (#2329 Deevi et al. Mechanism for the benefits of cetuximab in

Roche applies for drug license extensions  -  Apr 17, 2007
newratings.comThe application is for allowing the use of Xeloda (capecitabine) and Xelox (oxaliplatin), with or without Avastin (bevacizumab), for the treatment of

Oral Glutamine Helps Prevent Side Effects Caused by Eloxatin®  -  Apr 19, 2007
Cancer Consultants (press release),Oral glutamine is effective for preventing oxaliplatin-induced neuropathy in colorectal cancer patients. The Oncologist. 2007; 12: 312-319.

Roche Posts Strong First Quarter Sales – Upgrade of Core Earnings ...  -  Apr 18, 2007
PharmaLive.com (press release),In the US and the European Union, Roche has filed Xeloda in combination with oxaliplatin with or without Avastin in first-line metastatic colorectal cancer

Cetuximab Improves Overall Survival In Advanced Colorectal Cancer  -  Apr 17, 2007
Medical News Today,The study randomised 1298 patients with EGFR-expressing metastatic colorectal cancer who had failed oxaliplatin and a fluoropyrimidine to combination

AACR: Cetuximab Shows Survival Edge as Third-Line Colorectal ...  -  Apr 17, 2007
MedPage Today,Among patients who failed 5-FU or capecitabine therapy as well as irinotecan and oxaliplatin (Eloxatin), cetuximab on top of best supportive care was

Cetuximab and Irinotecan Combination Increases Survival in Metastatic  -  Apr 20, 2007
WebWire (press release),Patients eligible in the trial had to have shown resistance to the drug oxaliplatin, a platinum-based therapy commonly used in the treatment of colorectal

Cetuximab improves Survival In Advanced Colorectal Cancer Patients ...  -  Apr 20, 2007
Medical News Today (press release),...colorectal cancer whose disease was no longer responding to all available chemotherapy, including irinotecan, oxaliplatin and fluoropyrimidines.

Spectrum Pharmaceuticals Announces Data From Three Oncology ...  -  Apr 20, 2007
Medical News Today (press release),In preclinical studies, satraplatin was active in a number of various tumor models and in cells resistant to cisplatin, carboplatin and oxaliplatin.

Spectrum Pharmaceuticals Announces Data From Three Oncology ...  -  Apr 19, 2007
PR Newswire (press release),In preclinical studies, satraplatin was active in a number of various tumor models and in cells resistant to cisplatin, carboplatin and oxaliplatin.

Pharmacyclics Identifies Functional Biomarkers for its Novel HDAC ...  -  Apr 18, 2007
PharmaLive.com (press release),...such as gamma- irradiation, cisplatin, and oxaliplatin, and show the usefulness of using RAD51, an enzyme, as a biomarker to predict clinical efficacy.

Randomized Phase III Trial Showed ERBITUX Significantly Improved ...  -  Apr 17, 2007
PipelineReview.com (press release),...in Colorectal Cancer) enrolled 1298 irinotecan-naive mCRC patients whose disease was not responding to first-line oxaliplatin-based chemotherapy.

Study the First to Show Survival Benefits of Cetuximab in Patients ...  -  Apr 17, 2007
DG NewsThese patients had failed all other available forms of therapy, including irinotecan (96%) and oxaliplatin (97%). More than two thirds of patients had

Pro-Pharmaceuticals Issues Corporate Update  -  Apr 17, 2007
PharmaLive.com (press release),...oxaliplatin, paclitaxel, cisplatin, and bevacizumab (Avastin(R)). Results show that DAVANAT(R) exhibits a broad spectrum of activity with tested drugs.

Pro-Pharmaceuticals Issues Corporate Update  -  Apr 17, 2007
Business Wire (press release),...oxaliplatin, paclitaxel, cisplatin, and bevacizumab (Avastin ® ). Results show that DAVANAT ® exhibits a broad spectrum of activity with tested drugs.

ImClone Systems Cancer Drug ERBITUX Shows Higher Secondary ...  -  Apr 16, 2007
Trading Markets,It enrolled 1298 irinotecan-naive mCRC patients whose disease was not responding to first-line oxaliplatin-based chemotherapy. After randomization, patients

Randomized Phase III Trial Showed ERBITUX Significantly Improved ...  -  Apr 16, 2007
Business Wire (press release),...in Colorectal Cancer) enrolled 1298 irinotecan-naïve mCRC patients whose disease was not responding to first-line oxaliplatin-based chemotherapy.

S. Colin Neill Nominated to Pro-Pharmaceuticals Board of Directors  -  Apr 16, 2007
Genetic Engineering News (press release),DAVANAT(R), in combination with 5-FU, leucovorin, irinotecan, doxorubicin, oxaliplatin, paclitaxel, cisplatin, and bevacizumab (Avastin(R)).

S. Colin Neill Nominated to Pro-Pharmaceuticals Board of Directors  -  Apr 16, 2007
Business Wire (press release),DAVANAT ® , in combination with 5-FU, leucovorin, irinotecan, doxorubicin, oxaliplatin, paclitaxel, cisplatin, and bevacizumab (Avastin ® ).

Pharma Sector: Few Newsmakers Of The Week - Merck, Pfizer, Mylan ...  -  Apr 14, 2007
Trading Markets,But the study demonstrated that addition of Vectibix to Avastin, when used in combination with oxaliplatin- or irinotecan-based chemotherapy was only a more

Alpha-lipoic acid trial for chemotherapy-induced peripheral neuropathy  -  Apr 11, 2007
ScienceBlogs...is being investigated to minimize the peripheral neuropathy associated with platinum-based chemotherapy such as cisplatin or oxaliplatin.

Oncology Drug Development Update - EGFr-Targeted Drugs: Vectibix ...  -  Apr 5, 2007
Drug Newswire (press release),PACCE was evaluating the addition of Vectibix to a regimen of standard oxaliplatin- or irinotecan-based chemotherapy and bevacizumab (Avastin; Genentech),

Study Reviews Chemotherapy for Advanced Biliary Tract Cancer  -  Apr 4, 2007
Cancer Consultants (press release),Platinum chemotherapy drugs include Platinol® (cisplatin), Eloxatin® (oxaliplatin), and Paraplatin® (carboplatin). Because many of the reviewed studies had

Pro-Pharmaceuticals Announces Tampa General Hospital Dosing ...  -  Apr 4, 2007
PharmaLive.com (press release),The Company has been conducting clinical and pre-clinical studies with DAVANAT(R) in combination with 5-FU, leucovorin, irinotecan, doxorubicin, oxaliplatin

Pro-Pharmaceuticals Announces Tampa General Hospital Dosing ...  -  Apr 4, 2007
Business Wire (press release),The Company has been conducting clinical and pre-clinical studies with DAVANAT ® in combination with 5-FU, leucovorin, irinotecan, doxorubicin, oxaliplatin,

Pro-Pharmaceuticals Reports Fourth Quarter and Full Year 2006 ...  -  Apr 3, 2007
PharmaLive.com (press release),DAVANAT(r), in combination with 5-FU, leucovorin, irinotecan, doxorubicin, oxaliplatin, paclitaxel, cisplatin, and bevacizumab (Avastin(r)).

sNDA Submitted for Xelox  -  Mar 30, 2007
Cancer Consultants (press release),...of Xelox (Xeloda® (capecitabine) plus Eloxatin® (oxaliplatin)) with or without Avastin® (bevacizumab) for the treatment of metastatic colorectal cancer.

Snow has measure of hope New treatments help chances in recurrent ...  -  Mar 28, 2007
San Francisco Chronicle,Among the possible treatments Snow might receive are chemotherapy drugs, such as irinotecan and oxaliplatin, that poison cells.

Oral Cancer Drug Xeloda Receives Positive Opinion from the ...  -  Feb 23, 2007
PharmaLive.com (press release),The study aimed to establish the potential use of Xeloda (X) and oxaliplatin (O) in untreated patients. - Patients were randomised to one of four regimens:

NCCN Updates Colon Cancer Guidelines  -  Jan 29, 2007
PharmaLive.com (press release),The combination regimen CapeOX, which is capecitabine (Xeloda, Roche) and oxaliplatin (Eloxatin, sanofi-aventis), was added as an alternate option to the

Celebrex® Does Not Increase Effectiveness of FOLFOX  -  Feb 5, 2007
Cancer Consultants (press release),Phase II study of an optimized 5-fluourouracil-oxaliplatin strategy (OPTIMOX2) with celecoxib in metastatic colorectal cancer: A GERCOR Study.

Flaky idea: Pile snow in middle of road  -  Feb 1, 2007
Canyon Courier,My doc has temporarily suspended Oxaliplatin, a chemo drug that makes you feel lousy; therefore, last week’s session was more tolerable.

Pro-Pharmaceuticals Meeting Scheduled with the FDA  -  Feb 23, 2007
American Digital Networks (press release),DAVANAT(R), in combination with 5-FU, leucovorin, irinotecan, doxorubicin, oxaliplatin, paclitaxel, cisplatin, and bevacizumab (Avastin(R)).

Pro-Pharmaceuticals Collaborates with Chemwerth to Scale-up ...  -  Feb 20, 2007
PharmaLive.com (press release),DAVANAT(R), in combination with 5-FU, leucovorin, irinotecan, doxorubicin, oxaliplatin, paclitaxel, cisplatin, and bevacizumab (AVASTIN(R)).

Roche Posts Outstanding Results for 2006  -  Feb 7, 2007
PharmaLive.com (press release),Marketing applications are planned worldwide, except Japan, in the first half of 2007 for approval of a combination of Xeloda, oxaliplatin and Avastin for

Access Pharmaceuticals Appoints Esteban Cvitkovic, MD as Director ...  -  Feb 13, 2007
Drug Newswire (press release),Dr. Cvitkovic played a fundamental role in the registration strategy and post-registration development of cisplatin and oxaliplatin, and will be integral to

Gut Research Yields New Anti-Cancer Approach  -  Feb 5, 2007
Medical News Today (press release),...regimens feature 5-fluorouracil (5-FU) in combination with other chemotherapy drugs (oxaliplatin, irinotecan) and antibodies (bevacizumab, cetuximab).

Gut Research Yields New Cancer Approach  -  Feb 2, 2007
Media Newswire (press release),...feature 5-fluorouracil ( 5-FU ) in combination with other chemotherapy drugs ( oxaliplatin, irinotecan ) and antibodies ( bevacizumab, cetuximab ).

More drugs added to colon-cancer guide  -  Jan 29, 2007
United Press International...for treating the deadly disease, beyond the standard combination of fluorouracil, leucovorin and oxaliplatin -- known collectively as Folfox.

Appeal against Mayne Pharma dropped  -  Jan 8, 2007
The Australian,SANOFI Aventis has dropped its appeal against a UK High Court decision in favour of Australian cancer drug manufacturer Mayne Pharma's oxaliplatin products.

Australia's Mayne Pharma anti-cancer drug appeal dropped by Sanofi ...  -  Jan 8, 2007
Forbes,In May 2006, the High Court in the UK ruled in favor of Mayne Pharma in relation to patents for its oxaliplatin products which Sanofi appealed.

Breaking the myth  -  Jan 7, 2007
Express Pharma,This evaluated Erbitux monotherapy versus best supportive care after failure of irinotecan, oxaliplatin, and fluoropyrimidines. "The results of the Erbitux

Xeloda(R) Combination Meets Primary Endpoint In International ...  -  Dec 24, 2006
Medical News Today (press release),Study results showed that the chemotherapy combination XELOX (oral Xeloda plus oxaliplatin) is as effective in delaying disease progression as the

AFX NEWS BRIEFING: Pharmaceuticals and chemicals highlights to 09 ...  -  Jan 9, 2007
Hemscott,Sanofi-Aventis SA has decided not to proceed with its appeal against the UK High Court decision in favour of Mayne Pharma's anti-cancer drug oxaliplatin.

Erbitux® Combinations Evaluated in Rectal and Esophageal Cancer  -  Jan 2, 2007
Cancer Consultants (press release),Cetuximab in combination with capecitabine, oxaliplatin and concomitant radiotherapy (Cet-Capox-RT) as preoperative therapy for rectal cancer.

Adjuvant Therapy for Pancreatic Cancer  -  Jan 16, 2007
Journal of American Medical Association (subscription),Combination chemotherapy trials linked to gemcitabine, including cisplatin, irinotecan, oxaliplatin, and fluoropyrimidines, did not meet their statistical

Pro-Pharmaceuticals Provides Corporate Update of 2006 Achievements ...  -  Dec 22, 2006
Business Wire (press release),...trial for second line treatment of patients with metastatic colorectal cancer who failed combination therapies that included irinotecan or oxaliplatin.

Cetuximab (Erbitux®) Combinations Evaluated in Rectal and ...  -  Jan 2, 2007
Cancer Consultants (press release),Researchers from Germany presented data on a phase I/II study of cetuximab, Xeloda® (capecitabine) and Eloxatin® (oxaliplatin) and concomitant radiotherapy

Pro-Pharmaceuticals Appoints Dr. James Gourzis to its Board of ...  -  Dec 20, 2006
Genetic Engineering News (press release),DAVANAT(R), in combination with 5-FU, leucovorin, irinotecan, doxorubicin, oxaliplatin, paclitaxel, cisplatin, and bevacizumab (Avastin(R)).

Xeloda(R) Combination Meets Primary Endpoint In International ...  -  Dec 24, 2006
Medical News Today (press release),Study results showed that the chemotherapy combination XELOX (oral Xeloda plus oxaliplatin) is as effective in delaying disease progression as the

Xeloda Meets Primary Endpoint in Multinational Phase III Advanced ...  -  Dec 10, 2006
Earthtimes.orgStudy results showedthat the chemotherapy combination XELOX (oral Xeloda plus oxaliplatin) is aseffective in delaying disease progression as the

Metastatic colorectal cancer: Erbitux improves overall survival in ...  -  Dec 19, 2006
Xagena.it,...epidermal growth factor receptor-expressing metastatic colorectal cancer patients who have failed prior Oxaliplatin-based chemotherapy.

Roche cancer treatment Xeloda reaches primary endpoint in latest ...  -  Dec 10, 2006
Forbes,Study results showed that the chemotherapy combination XELOX -- consisting of oral Xeloda plus oxaliplatin -- was as effective in delaying disease

Xeloda ups survival in colorectal cancer  -  Dec 11, 2006
United Press International..."By demonstrating that Xeloda in combination with oxaliplatin was as effective as FOLFOX-4, these two studies provide the strongest evidence yet that Xeloda

Sales of Eloxatin for colorectal cancer are expected to slow in ...  -  Dec 7, 2006
Therapeutics Daily (subscription) (press release),Sales of Eloxatin for colorectal cancer are expected to slow in the coming years as generic oxaliplatin begins to enter the EU markets, according to a new

Pro-Pharmaceuticals Provides Corporate Update of 2006 Achievements ...  -  Dec 22, 2006
PharmaLive.com (press release),...trial for second line treatment of patients with metastatic colorectal cancer who failed combination therapies that included irinotecan or oxaliplatin.

Family, friends organize benefit dance for cancer treatment  -  Nov 28, 2006
Niagarathisweek.com,He is now taking a mix of drugs, Oxaliplatin and Avastin, drugs which are shipped from the US In December, Morris will visit his surgeon in Hamilton to see

Pro-Pharmaceuticals Appoints Dr. James Gourzis to its Board of ...  -  Dec 20, 2006
Genetic Engineering News (press release),DAVANAT(R), in combination with 5-FU, leucovorin, irinotecan, doxorubicin, oxaliplatin, paclitaxel, cisplatin, and bevacizumab (Avastin(R)).

Pro-Pharmaceuticals Appoints Dr. James Gourzis to its Board of ...  -  Dec 20, 2006
Business Wire (press release),DAVANAT ® , in combination with 5-FU, leucovorin, irinotecan, doxorubicin, oxaliplatin, paclitaxel, cisplatin, and bevacizumab (Avastin ® ).

MEABCO'S BP-Cx-1 Widens the Number of First Line Cystostatic Agents  -  Dec 14, 2006
Drug Newswire (press release),I find the ongoing experiments with modern platinum drugs, carboplatin and oxaliplatin, of considerable interest and potential. The extended scope of the

MEABCO'S BP-Cx-1 Widens the Number of First Line Cystostatic Agents  -  Dec 13, 2006
Earthtimes.orgI find theongoing experiments with modern platinum drugs, carboplatin and oxaliplatin,of considerable interest and potential.

Pro-Pharmaceuticals Announces Dosing of Patients with DAVANAT in ...  -  Nov 28, 2006
PipelineReview.com (press release),DAVANAT®, in combination with 5-FU, leucovorin, irinotecan, doxorubicin, oxaliplatin, paclitaxel, cisplatin, and bevacizumab (Avastin®).

Low Hematologic Toxicity Rate for Gemzar® and Ellence® in Advanced ...  -  Nov 28, 2006
Cancer Consultants (press release),Researchers from Italy have reported that the combination of Gemzar (gemcitabine) and Ellence (oxaliplatin) (GEMOX) has a good toxicity profile and

This site is for informational purposes only--it does not offer medical advice or sell health products. If you need assistance, contact your physician or healthcare professional